FibroGen, Inc. (FGEN) Forms $59.75 Double Top; LIVING CELL TECHNOLOGIES LTD ORDINARY SH (LVCLF) Sellers Increased By 8.81% Their Shorts

FibroGen, Inc. (FGEN) formed double top with $65.13 target or 9.00% above today’s $59.75 share price. FibroGen, Inc. (FGEN) has $4.90B valuation. The stock increased 3.91% or $2.25 during the last trading session, reaching $59.75. About 523,999 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has risen 52.86% since February 27, 2017 and is uptrending. It has outperformed by 36.16% the S&P500.

LIVING CELL TECHNOLOGIES LTD ORDINARY SH (OTCMKTS:LVCLF) had an increase of 8.81% in short interest. LVCLF’s SI was 86,500 shares in February as released by FINRA. Its up 8.81% from 79,500 shares previously. With 43,300 avg volume, 2 days are for LIVING CELL TECHNOLOGIES LTD ORDINARY SH (OTCMKTS:LVCLF)’s short sellers to cover LVCLF’s short positions. The SI to LIVING CELL TECHNOLOGIES LTD ORDINARY SH’s float is 0.02%. The stock decreased 2.27% or $0.0005 during the last trading session, reaching $0.0215. About shares traded. Living Cell Technologies Limited (OTCMKTS:LVCLF) has 0.00% since February 27, 2017 and is . It has underperformed by 16.70% the S&P500.

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore function in New Zealand. The company has market cap of $10.96 million. The companyÂ’s lead product is NTCELL, an alginate coated capsule, which is in Phase IIb clinical trial for the treatment of ParkinsonÂ’s disease. It currently has negative earnings. It has a research collaboration agreement with the Centre for Brain Research at the University of Auckland to identify additional neurodegenerative disease targets for clinical studies of NTCELL.

Among 8 analysts covering FibroGen Inc (NASDAQ:FGEN), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. FibroGen Inc had 16 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, July 29 by Citigroup. The rating was initiated by Lake Street with “Hold” on Wednesday, September 23. As per Friday, December 4, the company rating was initiated by Citigroup. Stifel Nicolaus maintained it with “Buy” rating and $80.0 target in Sunday, September 10 report. The rating was initiated by Mizuho on Wednesday, October 4 with “Hold”. The firm has “Buy” rating by Jefferies given on Tuesday, August 8. On Thursday, February 11 the stock rating was upgraded by Credit Suisse to “Outperform”. As per Tuesday, August 8, the company rating was maintained by Leerink Swann. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, October 18. The stock of FibroGen, Inc. (NASDAQ:FGEN) earned “Buy” rating by Jefferies on Monday, August 14.

Analysts await FibroGen, Inc. (NASDAQ:FGEN) to report earnings on March, 7. They expect $-0.28 EPS, up 48.15% or $0.26 from last year’s $-0.54 per share. After $-0.50 actual EPS reported by FibroGen, Inc. for the previous quarter, Wall Street now forecasts -44.00% EPS growth.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: